BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26780404)

  • 1. Amorphous powders for inhalation drug delivery.
    Chen L; Okuda T; Lu XY; Chan HK
    Adv Drug Deliv Rev; 2016 May; 100():102-15. PubMed ID: 26780404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large porous particles for respiratory drug delivery. Glycine-based formulations.
    Ogienko AG; Bogdanova EG; Trofimov NA; Myz SA; Ogienko AA; Kolesov BA; Yunoshev AS; Zubikov NV; Manakov AY; Boldyrev VV; Boldyreva EV
    Eur J Pharm Sci; 2017 Dec; 110():148-156. PubMed ID: 28479348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
    Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
    AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of extra-fine particles containing nanosized meloxicam for deep pulmonary delivery: In vitro aerodynamic and cell line measurements.
    Party P; Kókai D; Burián K; Nagy A; Hopp B; Ambrus R
    Eur J Pharm Sci; 2022 Sep; 176():106247. PubMed ID: 35760279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder pharmaceutical biologics for inhalation therapy.
    Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
    Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of IgG1 in spray-dried powders for inhalation.
    Schüle S; Schulz-Fademrecht T; Garidel P; Bechtold-Peters K; Frieb W
    Eur J Pharm Biopharm; 2008 Aug; 69(3):793-807. PubMed ID: 18477504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
    You Y; Zhao M; Liu G; Tang X
    J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
    Bosquillon C; Lombry C; Préat V; Vanbever R
    J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
    Razavi Rohani SS; Abnous K; Tafaghodi M
    Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders.
    Yu J; Romeo MC; Cavallaro AA; Chan HK
    Int J Pharm; 2018 Apr; 541(1-2):11-18. PubMed ID: 29454904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine as an excipient in spray dried powder for inhalation.
    Alhajj N; O'Reilly NJ; Cathcart H
    Drug Discov Today; 2021 Oct; 26(10):2384-2396. PubMed ID: 33872799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming challenges for development of amorphous powders for inhalation.
    Chang RYK; Chen L; Chen D; Chan HK
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1583-1595. PubMed ID: 32811193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
    Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
    Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J; Chan HK; Gengenbach T; Denman JA
    Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation Design of Dry Powders for Inhalation.
    Weers JG; Miller DP
    J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.